Phillips-Medisize and Exact Sciences (NSDQ:EXAS) today announced a collaboration to advance early cancer detection. The collaboration centers around Exact Sciences’ Cologuard, the first and only FDA-approved, non-invasive stool DNA screening test for colorectal cancer, according to a news release. Phillips-Medisize, a Molex company, said the collaboration will seek to focus on the patient experience through […]
Exact Sciences
The 10 most popular DeviceTalks Weekly Podcast episodes of 2020
Without the ability to gather for events and meetings, the DeviceTalks team launched the DeviceTalks Weekly Podcast to keep our medtech community talking. Over the span of 9 months and 39 episodes, we interviewed dozens of medtech leaders from startups to multinational corporations to hear how they’re managing through the challenges of 2020. Our episodes […]
MedTech 100 roundup: Stocks continue to plummet
Stocks in the medtech industry hit a wall two weeks ago, and it’s been a quick drop for them ever since. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 91.01 (Oct. 30), marking a 6.4% drop from the 97.02 points registered at the end […]
Exact Sciences to acquire Thrive for $2.15B
Exact Sciences (NSDQ:EXAS) announced today that it is acquiring cancer detection tech developer Thrive Earlier Detection for $2.15 billion. Under the agreement, Thrive will receive the total consideration of up to $2.15 billion, which includes $1.7 billion payable at closing, comprised of 65% of Exact Sciences common stock and 35% in cash, according to a […]
Report: “Unglamorous” medtech outshines biopharma in 2019
Medtech merger and acquisition deal announcements slowed in the first half of 2019, but the industry got a boost from Verily’s $1 billion round of funding — the largest ever for a medtech firm. The Verily round was twice the size of the biggest-ever VC deal for a biotech company, according to the Vantage Half-Year […]
Exact Sciences is successful: Here are the secrets that helped it grow
Kevin Conroy knew he was taking a risk when he became CEO of Exact Sciences: The company had twice failed to develop screening tests for colorectal cancer, and it was light on cash. But as he explained in a recent LinkedIn blog post, he had three friends diagnosed with colorectal cancer around the same time: “While […]
Phillips-Medisize’s increased business to benefit Molex plant in Arkansas
Phillips-Medisize today announced a doubling of production for an undisclosed fast-growing medical customer with a take-home diagnostic kit for cancer detection – with benefits for the plant that Phillips-Medisize’s parent Molex runs in Little Rock, Ark. Phillips-Medisize, which is based in Hudson, Wis., did not disclose the identity of the customer, which it described as a leader in consumable […]
Medtech stocks: the best and worst of Q1 2017
More than four-fifths of the 100 largest medical device companies in the world saw their stock prices increase during the first three months of 2017, according to a Medical Design & Outsourcing analysis of how the stocks of our Big 100 companies are faring. The situation suggests that even with the uncertainty around what the […]
New blood-based test could detect all lung cancer types
Exact Sciences and the Mayo Clinic recently collaborated on a blood-based lung cancer test that researchers say has shown high accuracy for detecting all stages of lung cancer. “These results reveal an opportunity to detect lung cancer from a simple blood draw,” said Kevin Conroy, chairman and CEO of Exact Sciences, in a news release. “Our […]
